New company updateBelow is the company update released this morning. Very strong in cash.
As of January 31, 2021, the Company had pro forma cash and cash equivalents of approximately $65.5 million when including proceeds of over $30 million in equity financings and $10 million in warrant exercises in January and February 2021.
In 2020, the Company generated $20 million in license revenue from its development and license agreements with Medtronic.
Under an ongoing development and license agreement with Medtronic and with the satisfaction of certain milestones thereunder, the Company expects to generate $21 million in additional license revenue in 2021.